UA65561C2 - Лікарський засіб для лікування лімфатичних пухлин - Google Patents

Лікарський засіб для лікування лімфатичних пухлин Download PDF

Info

Publication number
UA65561C2
UA65561C2 UA99095052A UA99095052A UA65561C2 UA 65561 C2 UA65561 C2 UA 65561C2 UA 99095052 A UA99095052 A UA 99095052A UA 99095052 A UA99095052 A UA 99095052A UA 65561 C2 UA65561 C2 UA 65561C2
Authority
UA
Ukraine
Prior art keywords
antibody
cells
specified
fact
cell
Prior art date
Application number
UA99095052A
Other languages
English (en)
Russian (ru)
Ukrainian (uk)
Other versions
UA65561A (en
Inventor
Ясуо Коісіхара
Ясусі Есімура
Original Assignee
Чугаї Сейяку Кабусікі Кайся
Чугаи Сейяку Кабусики Кайся
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Чугаї Сейяку Кабусікі Кайся, Чугаи Сейяку Кабусики Кайся filed Critical Чугаї Сейяку Кабусікі Кайся
Publication of UA65561A publication Critical patent/UA65561A/xx
Publication of UA65561C2 publication Critical patent/UA65561C2/uk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
    • C07K16/3061—Blood cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
UA99095052A 1997-02-12 1998-12-02 Лікарський засіб для лікування лімфатичних пухлин UA65561C2 (uk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP4141097 1997-02-12
PCT/JP1998/000568 WO1998035698A1 (en) 1997-02-12 1998-02-12 Remedies for lymphocytic tumors

Publications (2)

Publication Number Publication Date
UA65561A UA65561A (en) 2000-08-15
UA65561C2 true UA65561C2 (uk) 2004-04-15

Family

ID=12607597

Family Applications (1)

Application Number Title Priority Date Filing Date
UA99095052A UA65561C2 (uk) 1997-02-12 1998-12-02 Лікарський засіб для лікування лімфатичних пухлин

Country Status (19)

Country Link
US (2) US6503510B2 (de)
EP (1) EP0997152B1 (de)
KR (2) KR20000070989A (de)
CN (1) CN1191855C (de)
AT (1) ATE297219T1 (de)
AU (1) AU724133B2 (de)
BR (1) BR9811094A (de)
CA (1) CA2280875C (de)
DE (1) DE69830492T2 (de)
ES (1) ES2241114T3 (de)
HU (1) HUP0001136A3 (de)
IL (1) IL131381A0 (de)
NO (1) NO993866L (de)
PL (1) PL190065B1 (de)
RU (1) RU2177805C2 (de)
SK (1) SK110099A3 (de)
TR (1) TR199901949T2 (de)
UA (1) UA65561C2 (de)
WO (1) WO1998035698A1 (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW474991B (en) * 1993-10-15 2002-02-01 Toshio Hirano Membrane protein polypeptide having function of pre-B cell proliferation and the encoded gene thereof
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
JP3609026B2 (ja) * 1998-02-25 2005-01-12 中外製薬株式会社 抗hm1.24抗体の免疫化学的測定方法
KR20020025990A (ko) * 1999-08-23 2002-04-04 나가야마 오사무 에이치엠1.24 항원의 발현 증강제
WO2002057316A1 (en) 2000-12-28 2002-07-25 Kirin Beer Kabushiki Kaisha Novel monoclonal antibody
JP3986439B2 (ja) 2001-02-07 2007-10-03 中外製薬株式会社 造血器腫瘍の治療剤
ES2869895T3 (es) 2001-03-09 2021-10-26 Chugai Pharmaceutical Co Ltd Método de purificación de proteínas
US7858330B2 (en) 2001-10-19 2010-12-28 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US7888478B2 (en) * 2002-09-11 2011-02-15 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
US20050226869A1 (en) * 2001-10-19 2005-10-13 Genentech, Inc. Compositions and methods for the treatment of tumor of hematopoietic origin
WO2003068260A1 (fr) 2002-02-14 2003-08-21 Chugai Seiyaku Kabushiki Kaisha Produits pharmaceutiques en solution contenant des anticorps
US20030223998A1 (en) * 2002-02-27 2003-12-04 Lamb Lawrence S. Targeted immunotherapy of acute lymphoblastic leukemia (ALL)
US20080219974A1 (en) * 2002-03-01 2008-09-11 Bernett Matthew J Optimized antibodies that target hm1.24
JP4462964B2 (ja) * 2003-03-10 2010-05-12 第一三共株式会社 癌特異的抗原を標的とした抗体
US20070142627A1 (en) * 2003-08-01 2007-06-21 Chugai Seiyaku Kabushiki Kaisha Sugar-chain-altered anti-hm1.24 antibody
EP1693069B1 (de) * 2003-10-10 2013-07-24 Chugai Seiyaku Kabushiki Kaisha Mittel zur behandlung von soliden tumoren
KR101296931B1 (ko) * 2004-10-26 2013-08-14 추가이 세이야쿠 가부시키가이샤 변형된 당쇄를 갖는 항-글리피칸 3 항체
US20080299128A1 (en) 2006-06-20 2008-12-04 Myung Kim Effect of Bst2 on inflammation
US8329186B2 (en) 2004-12-20 2012-12-11 Isu Abxis Co., Ltd Treatment of inflammation using BST2 inhibitor
CN1865275B (zh) * 2005-05-17 2011-06-15 长春华普生物技术有限公司 对人b细胞肿瘤有治疗作用的人工合成的单链脱氧核苷酸
US7989595B2 (en) * 2005-06-20 2011-08-02 Genentech, Inc. Compositions and methods for the diagnosis and treatment of tumor
EP2064240A2 (de) 2006-09-18 2009-06-03 Xencor, Inc. Optimierte auf hm1.24 abzielende antikörper
MX2010004251A (es) 2007-10-16 2010-08-30 Sbi Biotech Co Ltd Anticuerpo anti-bst2.
TWI445716B (zh) 2008-09-12 2014-07-21 Rinat Neuroscience Corp Pcsk9拮抗劑類
US9123149B2 (en) * 2013-03-15 2015-09-01 Columbia Insurance Company Expert color system for color selection with color harmony and color emotion intelligence
CN107619443B (zh) * 2016-07-14 2020-08-14 深圳宾德生物技术有限公司 抗人和鼠cd317的单克隆抗体及其制备方法和应用
CN109748964B (zh) * 2017-11-01 2020-11-17 深圳宾德生物技术有限公司 CD317单链抗体317scFv、其编码序列及制备方法和应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5650150A (en) * 1990-11-09 1997-07-22 Gillies; Stephen D. Recombinant antibody cytokine fusion proteins
AU668349B2 (en) * 1991-04-25 1996-05-02 Chugai Seiyaku Kabushiki Kaisha Reconstituted human antibody against human interleukin 6 receptor
TW474991B (en) 1993-10-15 2002-02-01 Toshio Hirano Membrane protein polypeptide having function of pre-B cell proliferation and the encoded gene thereof
UA76934C2 (en) * 1996-10-04 2006-10-16 Chugai Pharmaceutical Co Ltd Reconstructed human anti-hm 1.24 antibody, coding dna, vector, host cell, method for production of reconstructed human antibody, pharmaceutical composition and drug for treating myeloma containing reconstructed human anti-hm 1.24 antibody
EP0972524A4 (de) * 1997-02-28 2001-03-28 Chugai Pharmaceutical Co Ltd Lymphozyten aktivierungsinhibitoren
AU750453B2 (en) 1997-10-03 2002-07-18 Chugai Seiyaku Kabushiki Kaisha Natural human antibody
WO1999018997A1 (en) * 1997-10-14 1999-04-22 Chugai Seiyaku Kabushiki Kaisha Potentiator for antibody against lymphoid tumor

Also Published As

Publication number Publication date
BR9811094A (pt) 2000-07-18
US20030113334A1 (en) 2003-06-19
KR20030097614A (ko) 2003-12-31
HK1026368A1 (en) 2000-12-15
HUP0001136A3 (en) 2002-02-28
AU5956398A (en) 1998-09-08
US6503510B2 (en) 2003-01-07
ES2241114T3 (es) 2005-10-16
KR100655979B1 (ko) 2006-12-08
CA2280875C (en) 2005-07-05
EP0997152A1 (de) 2000-05-03
NO993866D0 (no) 1999-08-11
DE69830492D1 (de) 2005-07-14
ATE297219T1 (de) 2005-06-15
CA2280875A1 (en) 1998-08-20
US20020037288A1 (en) 2002-03-28
KR20000070989A (ko) 2000-11-25
RU2177805C2 (ru) 2002-01-10
UA65561A (en) 2000-08-15
NO993866L (no) 1999-10-11
PL190065B1 (pl) 2005-10-31
WO1998035698A1 (en) 1998-08-20
AU724133B2 (en) 2000-09-14
PL335140A1 (en) 2000-04-10
TR199901949T2 (xx) 2000-01-21
CN1191855C (zh) 2005-03-09
SK110099A3 (en) 2000-08-14
IL131381A0 (en) 2001-01-28
DE69830492T2 (de) 2006-03-16
EP0997152B1 (de) 2005-06-08
CN1250381A (zh) 2000-04-12
EP0997152A4 (de) 2001-04-18
HUP0001136A2 (hu) 2000-08-28

Similar Documents

Publication Publication Date Title
JP3452062B2 (ja) Cdr―移植された抗体
CN113912725B (zh) 用于癌症治疗的钙粘蛋白-17特异性抗体和细胞毒性细胞
Seon et al. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
US20240245771A1 (en) Fully human antibody for human b7h3, chimeric antigen receptor and uses thereof
RU2177805C2 (ru) Средство, применяемое при лечении опухолей лимфатической ткани
UA124417C2 (uk) БІСПЕЦИФІЧНИЙ КОНСТРУКТ АНТИТІЛА, ЩО ЗВ'ЯЗУЄ EGFRvIII І CD3
UA125717C2 (uk) Конструкція антитіла до flt3 і cd3
WO2017130223A2 (en) A chimeric antigen receptor specific to b-cell maturation antigen, a recombinant expression vector and a method thereof
LV11624B (en) Immuno-stimulatory monoclonal antibodies
AU2018242408A1 (en) Chimeric antigen receptor
CN108997497A (zh) 特异结合人质膜膜泡关联蛋白pv-1的单克隆抗体及其制备方法与应用
US8394368B2 (en) Method for producing a composition for promoting survival of transplanted hematopoietic stem cell
CN116554327A (zh) 特异性结合c-Met的抗体、嵌合抗原受体及其应用
US20260061005A1 (en) Single-chain fragment variable targeting human pdgfr-beta and use thereof in car-t cell immunotherapy
CN102307900B (zh) 通过结合胞间粘附分子1调节树突细胞分化和功能的抗体及其用途
CN101073667B (zh) 淋巴细胞肿瘤抗体的增强剂
EP4545085A1 (de) Car-t-zellen gegen cd79b zur behandlung von non-hodgkin-lymphom
EP4620974A1 (de) Anti-afp/hla02-tcr-ähnlicher antikörper und verwendung davon
AU2024274106A1 (en) Antibody specifically binding to cd38, and preparation method therefor and use thereof
US20080318297A1 (en) Inhibition of Infiltration, and Cell Killing Agent
CN121991246A (zh) 一种特异性结合cd70和bcma的双靶向嵌合抗原受体及应用
JPH1030000A (ja) 腫瘍血管内皮表面の抗原を認識するモノクローナル抗体
HK1262482A1 (en) Cadherin-17 specific antibodies and cytotoxic cells for cancer treatment